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ABSTRACT
Multiple myeloma (MM) is a plasma cell malignancy characterized by the 
accumulation of tumor cells in the bone marrow (BM) and is associated with 
immunosuppression, angiogenesis and osteolysis. Myeloid-derived suppressor cells 
(MDSCs) represent a heterogeneous population of immature, immunosuppressive 
myeloid cells that promote tumor progression through different mechanisms.
In this work, we studied the contribution of MDSC subsets to different disease-
promoting aspects in MM. We observed an expansion of polymorphonuclear/
granulocytic (PMN-)MDSCs in two immunocompetent murine MM models, while 
this was not observed for monocytic (MO-)MDSCs. Both MDSC subpopulations from 
MM-bearing mice were immunosuppressive, but PMN-MDSCs displayed a higher 
suppressive potential. Soluble factors secreted by MM cells increased the viability of 
MDSCs, whereas the presence of MDSCs did not affect the proliferation of MM cells 
in vitro or in vivo. Interestingly, we observed a pro-angiogenic effect of PMN-MDSCs 
in the context of MM using the chick chorioallantoic membrane assay. Consistently, 
MM-derived PMN-MDSCs showed an up-regulation of angiogenesis-related factors and 
reduced PMN-MDSC levels were associated with less angiogenesis in vivo. Finally, we 
identified MO-MDSCs as osteoclast precursors.
These results suggest that MDSC subpopulations play diverging roles in MM. We 
show for the first time that PMN-MDSCs exert a pro-angiogenic role in MM.
INTRODUCTION
The plasma cell malignancy multiple myeloma 
(MM) is the second most frequent hematological 
malignancy and is characterized by the accumulation of 
monoclonal tumor cells in the bone marrow (BM). The BM 
invasion causes osteolytic bone destruction, giving rise to 
severe bone pain and pathological fractures in the vast 
majority of MM patients [1]. MM progression is facilitated 
by several disease-associated mechanisms, including 
angiogenesis [2] and immunosuppression [3]. The immune 
system is actively suppressed by MM cells through the 
secretion of suppressive factors and the recruitment of 
immune suppressive cells such as regulatory T cells (Tregs) 
[3] and myeloid-derived suppressor cells (MDSCs), a 
heterogeneous population of immature myeloid cells.
MDSCs have been shown to accumulate in several 
pathological conditions including cancer. In mice, they are 
characterized by the co-expression of the CD11b and Gr1 
surface molecules [4]. Two different MDSC subpopulations 
with distinct morphological, molecular and functional 
properties can be distinguished: a polymorphonuclear 
or granulocytic population (PMN-MDSCs), resembling 
immature neutrophils, and a mononuclear or monocytic 
population (MO-MDSCs). On a phenotypical level, they 
can be distinguished by the differential expression of 
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the Ly6G and Ly6C surface molecules, both recognized 
by the anti-Gr1 antibody. PMN-MDSCs present a 
CD11b+Ly6G+Ly6Cint phenotype, whereas MO-MDSCs 
are CD11b+Ly6G-Ly6Chigh. Both PMN- and MO-MDSCs 
suppress antigen-specific T-cell responses, even though 
they use different mechanisms [5, 6]. Interestingly, in a 
majority of murine tumor models, a preferential expansion 
of PMN-MDSCs has been observed [6]. MDSCs contribute 
to tumor progression not only by suppressing immune 
responses, but also by promoting tumor invasion and 
metastasis as well as tumor angiogenesis [7].
A pro-angiogenic role of total CD11b+Gr1+ MDSCs 
has been established in several murine models. In colorectal 
cancer and Lewis lung carcinoma (LLC), MDSCs 
promote angiogenesis through the production of matrix 
metalloproteinase 9 (MMP-9) and by the acquisition of 
endothelial cell properties in the tumor microenvironment 
[8]. Treatment with granulocyte-colony stimulating 
factor (G-CSF) promotes LLC and squamous carcinoma 
growth by promoting tumor angiogenesis, mediated by 
an increase in circulating endothelial progenitor cells and 
total MDSCs [9]. Moreover, in canine mammary cancer, 
an accumulation of interleukin (IL)-28-secreting MDSCs 
promotes the pro-angiogenic phenotype of tumor cells 
[10]. Regarding the involvement of MDSC subpopulations, 
a pro-angiogenic role of MO-MDSCs has been shown in 
murine lung, melanoma and prostate tumors, regulated by 
macrophage colony stimulating factor (M-CSF) signaling. 
Moreover, MO-MDSCs could contribute to a compensatory 
mechanism involved in resistance to antiangiogenic therapy 
by modulating the expression of MMP-9 [11].
In contrast to the murine MDSC phenotype, 
specific markers for human MDSCs are less well 
defined. Generally, human MDSCs are described as 
CD11b+CD33+HLA-DRlow/-. As in mice, granulocytic and 
monocytic subpopulations can be distinguished, suggested 
to be CD14-CD15+ or CD14+, respectively [12]. In MM 
patients, a first report described increased CD14+HLA-
DRlow/- MO-MDSC levels in the peripheral blood at 
diagnosis [13]. Conversely, other reports described 
increased levels of PMN-MDSCs in the peripheral blood 
and BM of MM patients [14–16]. In vitro, MDSCs isolated 
from MM patients are able to suppress T-cell responses 
[15, 16], induce Treg cells [16] and promote MM cell 
growth while MM cells induce MDSC development, 
indicating bidirectional interactions between MDSCs 
and myeloma cells [15]. In murine MM models, an early 
and transient accumulation of PMN-MDSCs has been 
observed in the BM, which is critical for MM progression 
by inhibiting T-cell responses [14]. In the 5T2 and 5T33 
murine MM models, a decrease of overall BM MDSC 
levels has been noted along with MM progression. 
However, in that report, an expansion of the monocytic 
fraction has been described within CD11b+ BM cells. Both 
MDSC subpopulations isolated from these mice were 
able to suppress antigen-specific T-cell proliferation [17]. 
Finally, MDSCs (CD11b+Gr1+) could serve as osteoclast 
progenitors in the 5TGM1 model, implicating these cells 
in MM-related bone disease [18].
Taken together, the data concerning the 
accumulation of MDSCs in MM are conflicting or fail 
to discern the two different MDSC subpopulations. In 
this work, we set out to study the kinetics of MDSCs 
in two immunocompetent murine models (i.e. 5TGM1 
and MOPC315.BM) and explore the contribution of the 
two different MDSC subpopulations to diverse disease-
promoting aspects in MM. More precisely, we studied 
the effects of MDSC subsets on MM proliferation and 
angiogenesis, as reports investigating the role of MDSCs 
on MM-associated angiogenesis are lacking. Further, it is 
currently not clear which MDSC subset differentiates into 
osteoclasts in the context of MM.
RESULTS
MDSC kinetics in two murine MM models
We first studied the kinetics of MDSC 
subpopulations during MM progression in the 
immunocompetent murine 5TGM1 and MOPC315.BM 
models using flow cytometry. In the BM, a significant 
decrease in percentages of PMN-MDSCs and a trend 
towards decreased MO-MDSC levels was noted in the 
5TGM1 model, whereas increased PMN-MDSC levels 
were observed in the MOPC315.BM model along with 
MM development (Figure 1A and 1B). In the blood, 
opposite changes were seen in PMN-MDSC levels, with 
an expansion in the 5TGM1 model and a decrease in the 
MOPC315.BM model. Finally, in the 5TGM1 model, MO-
MDSCs expanded transiently in the blood, but at the final 
disease stage their percentage was decreased compared 
to healthy controls (Figure 1A). Of note, higher levels 
of both MDSC populations were observed in the BM of 
naive C57BL/KaLwRij mice compared to naive Balb/c 
mice (day 0), and the opposite was observed in peripheral 
blood.
Thus, depending on the MM model, we observed 
different MDSC kinetics during MM development. 
However, expansions of PMN-MDSCs were noted 
in end-stage disease for both models, i.e. in the BM of 
MOPC315.BM-bearing mice and in the blood of 5TGM1-
bearing mice, which was not observed for MO-MDSCs.
In vitro and in vivo interactions between 
myeloma cells and MDSC subpopulations
We focused on the 5TGM1 model for further 
analysis of MDSC subpopulations, as this model has 
a higher MM infiltration rate than the MOPC315.BM 
model, which can be easily determined through GFP 
expression by 5TGM1 cells. Both MDSC subpopulations 
isolated from the BM of 5TGM1-bearing or healthy 
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mice presented typical morphological characteristics of 
both subsets (data not shown) and were able to suppress 
CD3/CD28-induced T-cell proliferation in a dose-
dependent manner (Figure 2A). Granulocytic MDSCs 
were more suppressive than the monocytic population, 
but no significant difference was seen in the suppressive 
phenotype of MDSCs isolated from MM-bearing mice or 
healthy controls.
In order to study the bi-directional interactions 
between MDSCs and 5TGM1 cells in vitro, we performed 
contact-independent co-cultures of 5TGM1 cells and 
MDSC subpopulations isolated from healthy C57BL/
KaLwRij mice. Using a MTT assay, we assessed the 
viability of MDSCs (prone to a relatively rapid cell death 
in vitro) and the proliferation of 5TGM1 cells, which 
survive and rapidly proliferate in vitro (thus MTT assay 
reflects their proliferative activity). The presence of soluble 
factors secreted by 5TGM1 cells significantly increased 
the viability of PMN-MDSCs and, to a lesser extent, the 
viability of MO-MDSCs (Figure 2B). In contrast, the 
presence of MDSC subpopulations had no effect on the 
proliferation of 5TGM1 cells in vitro (Figure 2B).
The effects of MDSC subpopulations on MM growth 
in vivo were studied on subcutaneous 5TGM1 solid tumor 
growth. The co-injection of PMN- or MO-MDSCs isolated 
from MM-bearing mice did not enhance 5TGM1 tumor 
growth in vivo (Figure 2C), even though a small trend 
towards faster tumor growth was observed at early time 
points. These results are in accordance with our in vitro 
observations. Furthermore, no significant differences 
were seen in solid tumor volumes after co-injection with 
MDSCs from MM-bearing or healthy control mice (data 
not shown). Finally, MDSC subset percentages and blood 
vessel counts within these solid tumors were not different 
between the experimental groups at the point of sacrifice 
(data not shown).
5TGM1 cells instruct granulocytic MDSCs to 
become pro-angiogenic
We used a gelatin-sponge chick chorioallantoic 
membrane (CAM) assay in order to directly study the 
effects of MDSC subpopulations isolated from healthy 
or myeloma-bearing mice on angiogenesis in vivo. The 
different MDSC subpopulations were implanted on the 
CAMs alone (Figure 3A and 3B) and in the presence of 
5TGM1 cells (Figure 3C). Figure 3A shows representative 
pictures of CAM assays in the presence of MDSC 
subpopulations (alone). Interestingly, the quantification 
of these CAM assays showed a pro-angiogenic effect 
Figure 1: Kinetics of MDSC subpopulations in MM-bearing mice. A. Percentages (mean ± SD gated on GFP- cells) of 
granulocytic (PMN-) or monocytic (MO-) MDSC populations in bone marrow or blood of C57BL/KaLwRij mice at day 0 (healthy controls, 
N=9) and 14 (N=4), 21 (N=4), 28 (N=5) or more than 30 days (N=10) after 5TGM1 inoculation. B. Percentages (mean ± SD) of PMN- or 
MO-MDSC populations in bone marrow or blood of Balb/c mice at day 0 (healthy controls, N=5) and 21 (N=5), 28 (N=5) or 35-38 days 
(N=6) after MOPC315.BM inoculation. Significant difference compared to healthy controls for PMN-MDSCs (*) or MO-MDSCs (#). *, 
#p<0.05; **, ##p<0.01; ***, ###p<0.001 (Mann-Whitney test).
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of PMN-MDSCs isolated from 5TGM1-bearing mice, 
in contrast to PMN-MDSCs isolated from healthy mice 
(Figure 3B). Furthermore, in the presence of 5TGM1 cells, 
the difference between the angiogenic phenotype of PMN-
MDSCs isolated from healthy mice or from 5TGM1-
bearing mice disappeared (Figure 3C). These results 
suggest that 5TGM1 cells are able to induce an angiogenic 
potential in PMN-MDSCs, as PMN-MDSCs obtained 
from healthy mice are also able to induce an angiogenic 
response after being co-cultured with 5TGM1 cells.
No significant pro-angiogenic effect of control and 
MM MO-MDSCs alone or in the presence of 5TGM1 cells 
was observed in this model (Figure 3B-3C). Of note, a 
trend towards less angiogenesis on CAM assays was seen 
in the presence of MO-MDSCs isolated from MM-bearing 
mice compared to controls.
Increased expression of pro-angiogenic factors in 
PMN-MDSCs from MM-bearing mice
We performed an angiogenesis proteome profiler 
array (R&D Systems) to assess the expression of different 
angiogenesis-related proteins in MDSC subsets isolated 
from 5TGM1-bearing mice (MM) compared to MDSCs 
from healthy mice (CTRL). Expression ratios (MM/CTRL) 
of the proteins expressed by MDSC subsets are summarized 
in Table 1. In PMN-MDSCs, several angiogenesis-related 
proteins are expressed (47 proteins) whereas less of these 
proteins were detected in MO-MDSCs (24 proteins). 
Interestingly, an increased expression was noted for the 
vast majority of these angiogenesis-related proteins (31 
proteins out of 47) in PMN-MDSCs isolated from MM-
bearing mice compared to controls, among which numerous 
proteins that have been identified as pro-angiogenic factors 
in the literature. In contrast, a decreased expression was 
noted for the vast majority of angiogenesis-related proteins 
(16 proteins out of 24) in MO-MDSCs from MM-bearing 
mice, mostly comprising pro-angiogenic factors.
These results are in accordance with a pro-
angiogenic role of PMN-MDSCs in the context of MM 
through the expression and up-regulation of numerous 
angiogenesis-related factors.
In vivo targeting of MDSCs results in a 
decreased myeloma-induced angiogenesis
Within the BM of 5TGM1-bearing mice that were 
treated with anti-Gr1 antibody, De Veirman et al described 
Figure 2: Effects of MDSC subpopulations on T-cell proliferation and interactions with MM cells. A. Suppression (mean ± 
SD) of CD3/CD28-induced T-cell proliferation by granulocytic (left) or monocytic (right) MDSCs isolated from 5TGM1-bearing (MM) or 
healthy (CTRL) C57BL/KaLwRij mice at various MDSC:splenocyte ratios (1:8→1:1). Proliferation was determined using a 3H-thymidin 
incorporation assay. Results represent 3-4 independent experiments and were assessed at least in triplicates within each experiment. 
*p<0.05; **p<0.01; ***p<0.001 (unpaired Student’s T test) when compared to T-cell proliferation without MDSCs (0% suppression). B. 
Percentage of viability/proliferation (mean ± SD), assessed using a MTT assay, of MDSCs from healthy C57BL/KaLwRij mice (top) or 
5TGM1 cells (bottom) after 48 hours of contact-independent co-culture in the presence of 5TGM1 cells or MDSC subpopulations isolated 
from healthy mice, respectively. Results represent 3 independent experiments. *p<0.05; ***p<0.001 (unpaired Student’s T test). C. 5TGM1 
solid tumor volume (mm3; mean ± SD) at sacrifice (N=6/group). 5TGM1 cells were subcutaneously injected into the right flank of mice 
with MDSC subpopulations isolated from 5TGM1-bearing mice (1:1 ratio).
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reduced levels of MDSCs, with a preferential depletion 
of PMN-MDSCs, leading to a reduced tumor load in the 
BM of these mice [19]. As a preferential depletion of the 
granulocytic MDSC fraction has been shown in the BM of 
these mice, we analyzed the microvessel density (MVD) 
in BM sections from these mice and found that it was 
significantly lower in the anti-Gr1-treated 5TGM1-bearing 
mice compared to vehicle-treated 5TGM1-bearing mice, 
i.e. 23 ± 3.5 versus 33.6 ± 3.3 vessels/field (p = 0.004), 
respectively (Supplementary Figure 1). These in vivo 
results reinforce our previous results that suggested a pro-
angiogenic role for PMN-MDSCs.
MO-MDSCs are able to differentiate into 
osteoclasts
Finally, we determined whether both MDSC 
subpopulations or, in contrast, only one of the two 
heterogeneous MDSC subsets contains osteoclast (OC) 
precursors. MO-MDSCs were able to differentiate 
into Tartrate-Resistant Acid Phosphatase (TRAP)+ 
multinucleated OCs in vitro, in contrast to PMN-MDSCs 
(Figure 4A-4B). This was further corroborated by the 
detection of specific TRAP activity in the supernatant 
of MO-MDSC-derived OC cultures (Figure 4C). RNA 
expression analysis showed a significant increase of factors 
that are crucial for OC differentiation and/or activity in 
OC-differentiated MO-MDSCs, i.e. dendritic cell-specific 
transmembrane protein (DC-STAMP), nuclear factor of 
activated T cells c1 (NFATc1), receptor activator of nuclear 
factor κ-B (RANK), cathepsin K (CTSK) and TRAP, 
confirming the OC phenotype of the differentiated MO-
MDSCs (Figure 4D).
However, no significant difference was noted 
between MM and CTRL MO-MDSCs in their ability to 
differentiate into OCs, in specific TRAP activity or in 
RNA expression of OC-related factors (Figure 4A-4D).
DISCUSSION
In this study, we focused on the relative contribution 
of granulocytic and monocytic MDSC subsets to different 
aspects of MM disease in murine models. Previous 
reports showed different results regarding the expansion 
of granulocytic or monocytic MDSC subpopulations in 
MM. In the current study, we observed opposite PMN-
MDSC kinetics in two murine models, i.e. the 5TGM1 
and MOPC315.BM models, and different MDSC levels in 
Figure 3: Effects of MDSC subpopulations on angiogenesis in gelatin-sponge CAM assays. A. Representative pictures (25x 
magnification) of gelatin-sponge CAM assays in the presence of MDSC subpopulations isolated from healthy (CTRL) or 5TGM1-bearing 
(MM) C57BL/KaLwRij mice. B–C. Quantification of angiogenesis in CAM assays, expressed in the number of blood vessels/sponge 
circumference (mean ± SD), in the presence of CTRL or MM MDSC subsets. (B) CAM assay in the presence of MDSC subpopulations 
alone (N=10-12/group). Negative controls (no MDSC) correspond to sponges containing complete medium without cells (N=5). (C) CAM 
assay in the presence of 5TGM1 cells and MDSC subpopulations. “No MDSC” controls correspond to sponges containing 5TGM1 cells 
without MDSCs (N=8-15/group). *p<0.05; **p<0.01 (unpaired Student’s T test).
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Table 1: Expression of angiogenesis-related proteins in BM MDSC subpopulations isolated from 5TMG1 myeloma-
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naive C57BL/KaLwRij compared to Balb/c mice. Schmid 
et al reported similar results, showing that the genetic 
background of C57BL/6 or Balb/c mice influenced the 
prevalence of MDSC subsets in the BM of naive mice, as 
well as their differentiation and function [20]. However, in 
both murine MM models we observed an expansion of the 
granulocytic MDSC fraction in different compartments of 
end-stage diseased animals, in contrast to the monocytic 
fraction. Our results suggest that PMN-MDSCs could 
be mobilized from the BM into peripheral blood in the 
5TGM1 model, whereas in the MOPC315.BM model 
these cells remain inside the BM. A recent report showed 
similar data, with a transient MO-MDSC expansion and 
a final increase in PMN-MDSCs (end-stage disease) in 
peripheral blood of C57BL/ KaLwRij mice bearing the 
5TGM1-parental 5T33 myeloma [19]. However, in our 
study some intermediate time points included a relatively 
small number of animals (N=4) and need confirmation 
in future studies. In the MOPC315.BM model, a strong 
downregulation of all hematopoietic precursor cells 
except those from myeloid lineage was reported early 
upon MM infiltration in the BM [21]. Thus, we can not 
exclude that the observed increases in MDSC percentages 
are partially caused by a reduction in total BM cells. 
Both MDSC subsets isolated from 5TGM1 myeloma-
bearing mice were immunosuppressive. The granulocytic 
fraction was more suppressive than the monocytic, as 
reported previously for MDSCs isolated from the BM 
of MM patients [15]. However, no difference was seen 
in the suppressive potential of MDSCs isolated from 
MM-bearing mice or healthy controls. In contrast to 
studies reporting that immature myeloid cells from naive 
mice are not immunosuppressive [14, 22], our results 
are in accordance with a report from Forghani et al who 
observed a comparable suppressive capacity for MDSCs 
isolated from the BM of tumor-free or mammary tumor-
bearing mice, suggesting a physiological role of MDSCs 
in the control of T-cell proliferation and activation in the 
BM microenvironment [23]. Similarly, no significant 
difference was reported between the suppressive potential 
of MDSCs isolated from MM patients or healthy donors 
[16].
MDSC subsets did not influence MM proliferation 
in vitro or in vivo. Of note, no significant differences in 
MDSC levels were seen in 5TGM1 solid tumors at the 
moment of sacrifice. MDSCs might have differentiated 
into mature myeloid cells, migrated towards other sites 
or have been prone to cell death. In addition, endogenous 
MDSCs from tumor-bearing mice could have been 
recruited towards the tumor site, annulling the initial 
differences in MDSC levels between groups. In future 
studies, it will be of interest to label co-injected MDSCs 
to distinguish them from endogenous MDSCs. In contrast 
to these findings, soluble factors secreted by MM cells 
increased the viability of both MDSC subsets, especially 
PMN-MDSCs, in vitro. Similar observations were made 
by De Veirman et al who showed that conditioned medium 
from 5T33MM cells increased the viability of total 
MDSCs [19].
We describe for the first time a pro-angiogenic 
role of MDSCs in the context of MM. Interestingly, this 
pro-angiogenic role is exerted by granulocytic MDSCs, 
in contrast to previous studies that described a pro-
angiogenic role of total MDSCs or monocytic MDSCs in 
other cancers [8–11]. The angiogenic phenotype of PMN-
MDSCs is dependent on the presence of MM cells in vivo 
or “ex vivo” (on CAM assays), suggesting that MM cells 
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A possible mechanism for the pro-angiogenic potential 
of PMN-MDSCs lies in the expression of numerous 
angiogenesis-related factors by these cells, among which 
a vast majority is up-regulated in granulocytic MDSCs 
isolated from MM-bearing mice compared to control 
MDSCs. Finally, our findings are reinforced by in vivo 
results, as we show a reduced blood vessel density in 
the BM of MM-bearing mice when less PMN-MDSCs 
are present. Of note, anti-Gr1-treated mice also display 
decreased levels of 5TGM1 infiltration within BM (4.8-
fold reduction compared to vehicle-treated mice). Thus, 
we cannot completely exclude an effect of reduced MM 
infiltration on the observed decrease of angiogenesis. 
In contrast, MO-MDSCs had no pro-angiogenic 
effect, expressed less angiogenesis-related factors than 
PMN-MDSCs, and the majority of these factors were 
expressed to a lesser extent in MO-MDSCs isolated from 
myeloma-bearing mice compared to control MDSCs. The 
Figure 4: Differentiation of MDSC subpopulations into osteoclasts. Osteoclast (OC) differentiation cultures were performed on 
MDSC subpopulations isolated from healthy (CTRL) or 5TGM1-bearing (MM) C57BL/KaLwRij mice (ND = non-differentiated control 
cultures). A. Representative pictures of TRAP staining on OC differentiation cultures (black bars = 50 μm). B. Total osteoclast number (mean 
± SD) counted in 3 fields/well after OC differentiation. OCs are defined as TRAP+-stained cells with multiple nuclei (≥3). C. TRAP activity 
(mean ± SD of enzymatic activity/mg of substrate) measured in culture supernatants. D. RNA expression levels (mean ± SD of 2-dCT) of 
different OC-related factors in MO-MDSCs at the end of the cultures. All the results represent at least 2-3 independent experiments. Within 
experiments, triplicates were performed for each condition. *p<0.05; **p<0.01, ***p<0.001 (unpaired Student’s T test).
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angiogenic potential of total MDSCs in tumor-bearing 
hosts was shown by others to be associated with the 
production of MMP-9 [8]. Here, we show that MMP-9 
protein expression is slightly increased in granulocytic and 
decreased in monocytic MM MDSCs.
Even though MO-MDSCs do not seem to play a role 
in MM-related angiogenesis, this subpopulation may be 
implicated in MM-associated osteolytic bone disease, as 
we identified these cells as osteoclast precursors. Zhuang 
et al [18] demonstrated that MDSCs from 5TGM1-
bearing mice could differentiate into osteoclasts in vitro 
and in vivo. However, they did not identify the specific 
MDSC subpopulation that contains OC progenitors, 
as they only considered total MDSCs (CD11b+Gr1+). 
Despite an important heterogeneity within both MDSC 
subpopulations, we showed that the PMN-MDSC subset 
does not contain any cellular fraction able to differentiate 
into OCs. In contrast to Zhuang et al, we did not see 
significant differences in OC differentiation from MO-
MDSCs isolated from MM-bearing or control mice. 
Similarly, reports on OC differentiation in breast cancer 
bone metastasis only considered total MDSCs and not 
individual subsets [24, 25].
Targeting of total MDSCs using anti-Gr1 antibodies 
or 5-fluorouracil in the murine 5TGM1 or 5T33MM 
models, respectively, showed promising results with a 
significant reduction of MM burden [19]. However, insight 
into the mechanisms by which this occurs is lacking and 
a direct effect of these strategies on myeloma cells should 
be investigated. In future studies, it would be interesting 
to target more specifically the granulocytic or monocytic 
MDSC subpopulations in myeloma, with the aim to 
reduce MM-related immune suppression, angiogenesis or 
osteolytic bone disease, and thus reduce MM progression. 
Notably, blocking of the programmed cell death (PD) 1 
receptor and its ligand, PD-L1, which respectively present 
increased expression levels on immune effector cells 
and MDSCs in MM patients, inhibited MDSC-mediated 
immune suppression. In addition, as MM cells express 
high levels of PD-L1, blockade of this axis also directly 
inhibits stromal cell-induced MM growth, suggesting a 
therapeutical interest of targeting the PD-1/PD-L1 axis in 
MM [26].
In conclusion, we show a preferential expansion 
of granulocytic MDSCs in two different murine MM 
models, even though the expansion occurs in different 
compartments. Furthermore, the granulocytic subset 
has a higher immunosuppressive capacity than MO-
MDSCs. We describe for the first time a pro-angiogenic 
role of granulocytic MDSCs in the context of MM. Our 
results suggest that myeloma cells instruct PMN-MDSCs 
to become pro-angiogenic by inducing changes in the 
expression of multiple angioregulatory factors by PMN-
MDSCs. Thus, we determined that the granulocytic 
MDSC subpopulation plays a major role in different 
myeloma-promoting disease aspects and we showed 
that the monocytic MDSC subset contains osteoclast 
precursors, demonstrating that MDSC subpopulations play 
diverging roles in MM.
MATERIALS AND METHODS
Mice
C57BL/KaLwRijHsd mice were purchased from 
Harlan laboratories B.V. (Horst, Netherlands) and Balb/cJ 
mice from Jackson Laboratory (Bar Harbor, USA). Both 
strains were bred at the animal facility of our institute and 
mice were used for experiments when they were between 
10- to 14-wk-old. Animal welfare was assessed at least 
once per day, and all efforts were made to minimize 
animal suffering during the experiments. Experimental 
procedures used in this investigation were approved by 
the Institutional Animal Care and Use Ethics Committee 
of the University of Liège (Belgium).
Myeloma cell lines and models
Two murine myeloma cell lines resulting in MM 
disease after intravenous (i.v.) injection to syngeneic 
mice were used. The selection of the Balb/c-derived 
MOPC315.BM cell line, kindly provided by B. Bogen 
(University of Oslo, Oslo, Norway), and the labeling 
with luciferase gene have been described previously 
[27, 28]. The establishment of the 5TGM1 cell line and 
eGPF-transfected 5TGM1 cells, originating from C57BL/
KaLwRij mice and kindly provided by G.R. Mundy and 
C.M. Edwards (Vanderbilt University, Nashville, TN, 
USA), has been described previously [29, 30]. Both cell 
lines were maintained in culture at 37°C in 5% CO2, 
using RPMI 1640 medium for MOPC315.BM cells or 
Dulbecco’s Modified Eagle Medium for 5TGM1 cells, 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and Penicillin/Streptomycin (100 U/ml) 
(=complete medium). All cell culture products were 
purchased from Lonza (Verviers, Belgium).
In vivo experiments for both MM models (i.v. 
injections) and monitoring of MOPC315.BM tumor 
development by bioluminescence were performed as 
previously described [31, 32]. For 5TGM1 solid tumor 
growth, 5TGM1 cells were suspended in phosphate 
buffered saline (PBS) containing 1 mg/ml of matrigel 
and were injected subcutaneously (2.5x105 cells/200μl/
mouse) into the right flank of C57BL/KaLwRij mice. For 
these solid tumor experiments, mice in all groups were 
sacrificed when tumors exceeded 1 cm or when skin 
ulcerations appeared (4 mice/group were sacrificed at day 
18 after injection, all the other mice at day 22).
Isolation of MDSC subpopulations
BM from tibias, femurs and spine was harvested 
from 5TGM1-bearing or healthy C57BL/KaLwRij mice 
and homogenized in sterile culture medium. Red blood 
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cells were lysed using a RBC lysis buffer (eBioscience, 
San Diego, USA) and cells were washed with PBS and 
filtered through a 70 μM nylon membrane to obtain final 
cell suspensions. More than 90% of CD11b+ BM cells 
are Ly6G+ or Ly6C+ MDSCs. MDSC subpopulations 
were isolated from BM cells using magnetic cell sorting. 
Granulocytic MDSCs were isolated on a LS column 
through a positive selection for Ly6G using the mouse 
anti-Ly6G microbead kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s 
instructions. The Ly6G- fraction was further depleted for 
residual Ly6G+ cells using a LD column, followed by a 
positive selection for CD11b using a LS column and 
mouse/human CD11b microbeads (Miltenyi Biotec) to 
obtain the monocytic MDSC fraction. Purity was assessed 
for each fraction using flow cytometry.
Suppression of T-cell proliferation
Spleens were harvested from C57BL/KaLwRij 
mice and cell suspensions were obtained as described 
above. Splenocytes (1x105/well) were cultured in 
96-well plates using complete RPMI 1640 medium 
containing 5  μM of 2-mercaptoethanol (Gibco by Life 
Technologies, Gent, Belgium). MDSC subsets were 
added (final culture volume 200 μl/well) at different 
MDSC:splenocyte ratios (1:8; 1:4; 1:2; 1:1) and T-cell 
proliferation was induced by adding 1 μl/well of mouse 
T-activator CD3/CD28 dynabeads (Gibco). Proliferation 
was assessed after 72 hours of culture by adding 0.33 
μCi of [methyl-3H] thymidin (Perkin Elmer, Waltham, 
USA) to each well for the last 18 hours of culture. DNA 
was harvested on Multiscreen Harvest Plates (Millipore, 
Carrigtwohill, Ireland) using Filter Mate Harvester 
(Perkin Elmer). Plates were dried for 3-4 hours before 
adding 25 μl/well of Microscint-O (Perkin Elmer) 
and measuring radioactivity (c.p.m.) with a TopCount 
NXT Microplate Scintillation counter (Perkin Elmer). 
Suppression was calculated as follows: Suppression (%) = 
[1 – (Proliferation with MDSCs/ proliferation without 
MDSCs)] x 100.
MDSC and 5TGM1 viability/proliferation 
in vitro
MDSC subpopulations were isolated from 
healthy C57BL/KaLwRij mice as described above. 
Contact-independent co-cultures of MDSCs (2x106) 
and 5TGM1 cells (5x105) were performed using 0.4 μM 
pore size transwell inserts (ThinCert, Greiner Bio-one, 
Frickenhausen, Germany). After 48 hours, MDSCs and 
5TGM1 cells were harvested and viability/proliferation 
was assessed using the cell proliferation kit I (MTT) from 
Roche Applied Science (Mannheim, Germany) following 
the manufacturer’s instructions. Absorbance at 570 nm was 
measured using a Wallac 1420 Victor2 microplate reader 
(Perkin Elmer). Viability/proliferation was expressed in 
percentage relative to MDSCs or 5TGM1 cells cultured 
alone (=100%).
Flow cytometry
Cell suspensions were obtained from spleen, 
bone marrow or peripheral blood as described above. 
Extracellular staining was performed in PBS containing 
3% FBS and antibodies were incubated for 30 min 
at 4°C. MDSC levels were determined by gating on 
CD11b+Ly6G+Ly6Cint/low cells (PMN-MDSCs) or 
CD11b+Ly6G-Ly6C+ cells (MO-MDSCs). Anti-mouse 
CD11b/APC (M1/70) was purchased from eBioscience 
(San Diego, USA) and Ly-6G/Pacific Blue (1A8) and Ly-
6C/PECy7 (HK1.4) were purchased from Biolegend (San 
Diego, USA).
Chick chorioallantoic membrane (CAM) assay
Chicken eggs were disinfected and 8-9 ml of 
albumen were aspirated in order to dissociate the CAM 
from the egg shell membrane 3 days after fertilization. 
An observation window was carefully cut into the shell, 
followed by re-injection of 4-5 ml of albumen below 
the CAM. The window was covered during further 
incubations in an egg incubator at 37°C and 80% 
humidity. We adapted a gelatin-sponge CAM assay from 
previous reports [33–35] using Gelfoam gelatin sponges 
(Pharmacia and Upjohn Company, Kalamazoo, USA), cut 
into 1-2 mm3 cubes, as support for non-adherent cells as 
previously described for macrophages [36]. The sponge 
was implanted on the CAM on day 9 post-fertilization and 
MDSCs (2.5x105 cells) and/or 5TGM1 cells (5x104 cells) 
were suspended in complete medium (5 μl) and placed on 
the sponge. At day 13 or 16, respectively, eggs incubated 
with MDSCs alone or with MDSCs in the presence of 
5TGM1 cells were placed during 30 minutes at -20°C and 
CAMs were fixed in ovo using a 4% paraformaldehyde 
solution. CAM portions containing the sponges were 
excised, observed using a MZ75 stereomicroscope 
(Leica Microsystems, Wetzlar, Germany) at 12.5x or 25x 
magnification and pictures were taken using the Leica 
Acquire Software (Leica Microsystems). Angiogenesis 
was quantified by a person blinded to the identity of 
samples, by counting the number of sponge-directed blood 
vessels on the CAM-sponge interface. This number was 
divided by the circumference of the corresponding sponge, 
calculated using the length and width of the sponge 
[circumference = Π x √(2x((length/2)2 + (width/2)2))] 
measured using the ImageJ software (National Institutes 
of Health, USA).
Angiogenesis-related protein array
Mouse angiogenesis proteome profiler array (R&D 
Systems, Minneapolis, USA) was performed on cell 
lysates from MDSC subpopulations isolated from 5TGM1 
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myeloma-bearing (MM) or healthy C57BL/KaLwRij 
control mice (CTRL) following the manufacturer’s 
instructions. Signals were quantified using the QuantityOne 
1-D Analysis Software (Biorad, Hercules, USA). Mean 
values of background signals (negative control spots) 
were substracted from mean values of analyte spots for 
each membrane, and MM/CTRL expression ratio was 
determined for proteins expressed by MDSCs.
In vivo treatment with anti-Gr1 antibody
5TGM1 cells were intravenously inoculated to 
syngeneic mice (1 × 106 cells/mouse). One day later, 
treatment was started with 200 μg/mouse of anti-
Gr1 antibody (RB6–8C5 purchased from BioXCell, 
West Lebanon, NH) every two days. When first mice 
showed signs of disease, all mice were sacrificed. CD31 
immunostaining and subsequent microvessel density 
(MVD) quantification were performed on BM sections 
from these mice as described previously [37].
Osteoclast differentiation
MDSC subsets isolated from 5TGM1 myeloma-
bearing or healthy C57BL/KaLwRij control mice were 
suspended in differentiation medium, i.e. α-Minimum 
Essential Medium supplemented with 10% heat-
inactivated FBS, Penicillin/Streptomycin (100 U/ml), 
Glutamine (2mM), 20 ng/ml M-CSF (Peprotech, Rocky 
Hill, USA) and 100 ng/ml receptor activator of nuclear 
factor κ-B ligand (RANKL, Peprotech). Using 48-well 
plates (Greiner Bio-One), 1.25 × 105 cells were plated into 
each well and cultured for 5-6 days at 37°C and 5% CO2. 
In non-differentiated (ND) control wells, no RANKL was 
added to the medium. Osteoclast staining was performed 
using Leukocyte Tartrate-Resistant Acid Phosphatase 
(TRAP) kit (Sigma-Aldrich, St. Louis, USA) following 
the manufacturer’s instructions. For the quantification of 
specific TRAP activity, culture supernatants (10 μl) were 
added to a p-nitrophenylphosphate (7.6 mM) sodium 
acetate-tartrate solution (Sigma-Aldrich) and incubated 
1h at 37°C. The reaction was stopped by the addition 
of NaOH and absorbance of the yellow enzymatic 
product p-nitrophenyl (pNP) was measured at 405 nm. 
Absorbance values were compared to a pNP standard 
curve and specific enzymatic activity was calculated [38].
RNA expression
RNA was isolated using the RNeasy Mini kit (Qiagen, 
Venlo, Netherlands) according to the manufacturer’s 
instructions. Genomic DNA was removed using recombinant 
RNase-free DNaseI (Roche, Vilvoorde, Belgium). cDNA 
synthesis was performed on RNA (100 ng) with random 
hexamer primers using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche). Quantitative real-time PCR 
(qPCR) was performed with KAPA SYBR FAST qPCR 
kit (KAPA biosystems, Wilmington, USA) on Light cycler 
480 (Roche). All primers were synthesized by Integrated 
DNA Technologies (Leuven, Belgium) and are listed in 
Supplementary Table 1. RNA expression levels (2-dCT) were 
calculated using actin and β-2 microglobulin reference 
genes.
Statistics
Statistical significance between murine experimental 
groups was determined using the Mann-Whitney test 
calculated with the Prism Software (Graph Pad Software, 
San Diego, CA). An unpaired Student’s T-Test performed 
with Excel software was used to determine statistical 
significance for other experiments.
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